By Adrian Devitt-Lee | Originally published by ProjectCBD.org

With cannabidiol (CBD) set to be widely available in pharmaceutical and herbal preparations, scientists are taking a closer look at CBD-drug interactions.

Cannabidiol is a safe, non-intoxicating, and non-addictive cannabis compound with significant therapeutic attributes, but CBD-drug interactions may be problematic in some cases.

CBD and other plant cannabinoids can potentially interact with many pharmaceuticals by inhibiting the activity of cytochrome P450, a family of liver enzymes. This key enzyme group metabolizes most of the drugs we consume, including more than 60 percent of marketed meds.

Three national polling agencies all recently showed that respondents had a slim but favorable view of marijuana. When considering just the medicinal uses of marijuana, respondents had an even more favorable view of the still-illicit drug.

It's not hard to see why marijuana has garnered so much favor in recent years, and why 23 states have allowed marijuana to be legalized for medicinal use. For states, marijuana offers a source of new revenue via taxes that could help fund education, transportation, and infrastructure, or even create jobs. For medical marijuana users, it represents a potential new pathway to help alleviate or even cure symptoms of various chronic or terminal diseases.

GW Prescription drugs ended up 7.6% yesterday after saying in a press launch headline that the corporate had "Constructive Proof of Idea Knowledge in Schizophrenia" for its cannabidiol, or CBD, drug.

Sounds nice, proper? With proof of idea in hand, the corporate simply wants to verify the part 2 outcomes and every thing is grand. Hooray for science. And medical marijuana derivatives. And sufferers. And buyers.

There’s only one drawback: proof of idea implies that you simply had a speculation, examined it, and it turned out to work, albeit on a scale smaller than is important to get the drug permitted.

Real, life-changing medical advances are being blocked for fear of ‘designer babies’; humane laws are stymied because of things they do not propose

Well, of course the Assisted Dying Bill failed. It mattered not a jot that an overwhelming majority of public opinion urged its success; it was always going to fail and the only surprising thing is that anybody is surprised. I’ll bet my teeth on a few more certainties, too. Last week the required 200,000 people put down their spliffs long enough to sign a petition in favour of decriminalising cannabis and thus, in October, the matter will be debated by MPs. Proponents, however, really should not bother — they will lose, regardless.

It is possible to access medical therapy with the use of drugs based on cannabis, the Polish Health Ministry has said.

Could it be possible that we have misinterpreted the health benefits of marijuana on diabetes risk?

A new study certainly intimates this, stating that it is quite possible those who use marijuana—even those who no longer use it—are at a higher risk for developing prediabetes.

According to Vanderbilt University assistant professor of medicine in the endocrinology department, Shichun Bao, MD, PhD, the study still needs more review but does provide, at least, a lot of caution.

Richert teaches in the department of history at the University of Saskatchewan.

In the award-winning 2013 movie, Dallas Buyers Club, we are exposed to heroic patient activism during the AIDS crisis in the United States.

Based on the true story of AIDS-stricken Ron Woodroof, a hard-partying Texas tradesman, the film shows a strikingly thin Matthew McConaughey battle his sickness and the legal authorities in Texas.

Woodroof, who's unhappy with his illegally purchased AIDS medicine, and on the edge of death, seeks out alternative and experimental drugs from a doctor in Mexico. Then Ron, being the savvy entrepreneur that he is, quickly establishes a club (a dispensary) to sell his unregulated, sometimes dangerous, imported medicines.

What is Happening?